BioCryst Pharmaceuticals, Inc. (BCRX)
8.47
-0.05
(-0.59%)
USD |
NASDAQ |
Oct 30, 16:00
8.465
0.00 (0.00%)
After-Hours: 20:00
BioCryst Pharmaceuticals Cash from Investing (Quarterly) : -110.15M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -110.15M |
| March 31, 2026 | -268.65M |
| December 31, 2025 | -83.49M |
| September 30, 2025 | 13.57M |
| June 30, 2025 | 29.13M |
| March 31, 2025 | 27.10M |
| December 31, 2024 | 17.80M |
| September 30, 2024 | 8.489M |
| June 30, 2024 | -2.449M |
| March 31, 2024 | 28.76M |
| December 31, 2023 | -28.47M |
| September 30, 2023 | 23.12M |
| June 30, 2023 | -19.04M |
| March 31, 2023 | -107.11M |
| December 31, 2022 | 77.22M |
| September 30, 2022 | -69.54M |
| June 30, 2022 | -97.44M |
| March 31, 2022 | -38.47M |
| December 31, 2021 | -11.12M |
| September 30, 2021 | 7.747M |
| June 30, 2021 | 4.504M |
| March 31, 2021 | 14.67M |
| December 31, 2020 | 21.41M |
| September 30, 2020 | -34.06M |
| June 30, 2020 | -4.932M |
| Date | Value |
|---|---|
| March 31, 2020 | 10.72M |
| December 31, 2019 | 16.26M |
| September 30, 2019 | 23.51M |
| June 30, 2019 | 22.28M |
| March 31, 2019 | 15.88M |
| December 31, 2018 | -3.167M |
| September 30, 2018 | -9.525M |
| June 30, 2018 | 1.533M |
| March 31, 2018 | 15.93M |
| December 31, 2017 | -57.38M |
| September 30, 2017 | 1.963M |
| June 30, 2017 | -23.35M |
| March 31, 2017 | 14.13M |
| December 31, 2016 | -9.721M |
| September 30, 2016 | 19.03M |
| June 30, 2016 | 10.90M |
| March 31, 2016 | 3.06M |
| December 31, 2015 | -1.525M |
| September 30, 2015 | -18.14M |
| June 30, 2015 | 7.072M |
| March 31, 2015 | -3.948M |
| December 31, 2014 | -53.09M |
| September 30, 2014 | 4.865M |
| June 30, 2014 | 9.266M |
| March 31, 2014 | -1.023M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Amgen, Inc. | -569.00M |
| Halozyme Therapeutics, Inc. | -62.66M |
| Neurocrine Biosciences, Inc. | -135.40M |
| Agenus, Inc. | 0.267M |
| Anika Therapeutics, Inc. | -1.28M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 103.98M |
| Cash from Financing (Quarterly) | -10.79M |
| Free Cash Flow | 356.23M |
| Free Cash Flow Per Share (Quarterly) | 0.3913 |
| Free Cash Flow to Equity (Quarterly) | 125.21M |
| Free Cash Flow to Firm (Quarterly) | 125.19M |
| Free Cash Flow Yield | 17.77% |